Scaffold for the enlarged heart
Cincinnati Children's Hospital Medical Center researchers have identified a scaffold protein, calcium and integrin binding 1, whose expression correlates with the development of cardiac hypertrophy-a condition for which only indirect treatments for related conditions are available.1 The protein's key selling point as a drug target is that it is upregulated only during pathologic hypertrophy; however, its lack of enzymatic activity could make it difficult to inhibit.
Cardiac hypertrophy-enlarged heart-can result from chronic hypertension, aortic stenosis or myocardial infarction (MI) and is a leading risk factor for heart failure. However, hypertrophy also is an important defense during exercise because it helps prevent damage due to increased stress and pressure.2
Rather than tease apart the mechanisms underlying the good and bad forms of hypertrophy,